Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Buyout framework

<< Previous

Bullboard Posts

Next >>

Comment by Proinvest2020on Oct 26, 2020 9:21am

109 Views

Post# 31780522

RE:RE:RE:RE:Buyout framework

Ahh ok... so filed for the rights... guess i heard what I wanted to hear. Not sure if there would be a reason to not grant the right to use it for resp. illness.

Thats a big if ...

Worth the risk for me if the drug works as expected.

Not so Pro I guess..lol!

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December